Point72 Asset Management
ACAD icon

Point72 Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Point72 Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$305K Buy
+13,700
New +$327K ﹤0.01% 3358
2018
Q2 		– Sell
-400,000
Closed -$8.99M – 943
2018
Q1 		$8.99M Buy
+400,000
New +$11.1M 0.04% 448
2017
Q4 		– Sell
-500,000
Closed -$18.8M – 882
2017
Q3 		$18.8M Buy
+500,000
New +$16.3M 0.08% 273

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Point72 Asset Management's ACAD Position: Q1 2026 in Review

Point72 Asset Management reduced its Acadia Pharmaceuticals (ACAD) stake by 24% in Q1 2026, selling an estimated $19.1M and leaving 2,577,916 shares worth $57.4M. The position accounts for 0.07% of the portfolio, ranked #317.

Point72 Asset Management first reported a position in ACAD in Q2 2014 and has held it in 38 quarters since. The position peaked at $97.9M in Q1 2018. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Point72 Asset Management held 2,577,916 shares of Acadia Pharmaceuticals worth $57.4M as of Q1 2026.
  • Point72 Asset Management sold 799,395 Acadia Pharmaceuticals shares in Q1 2026, an estimated $19.1M.
  • Acadia Pharmaceuticals made up 0.07% of Point72 Asset Management's portfolio in Q1 2026, its #317 holding.
  • Point72 Asset Management first reported a position in Acadia Pharmaceuticals in Q2 2014 and has held it in 38 quarters since.
  • Point72 Asset Management's Acadia Pharmaceuticals position peaked at $97.9M in Q1 2018.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.